The recent surge in Jinhai Medical Technology (SEHK:2225) has become the story. A price to book multiple near 64x, far above sector norms, is now forcing investors to question how much optimism is already priced in.
Recent trading tells a mixed story. The 1-day share price return of 1.32% follows a 7-day share price decline of 9.41% and a 30-day share price fall of 32.40%, yet Jinhai Medical Technology still carries a year-to-date share price gain of 210.48% and a 3-year total shareholder return close to 5x. This points to momentum that has cooled in the short term but remains very strong over a multi year horizon.
Spot opportunities trading on more grounded valuations by scanning our hand picked 195 high quality undervalued stocks that pair balance sheet strength with more modest expectations than Jinhai Medical Technology.Bulls see Jinhai Medical Technology as a high conviction rerating story, while bears view a 64x P/B and recent pullback as a warning. Which side do the balance sheet and current valuation actually support?
Price to book of 64x for Jinhai Medical Technology: Is it justified?
Valuation for Jinhai Medical Technology right now is being anchored by its P/B multiple. A P/B of 64x against a HK$3.85 last close pulls attention straight to how much investors are willing to pay for each dollar of net assets compared to peers.
The price to book ratio compares the market value of the equity to the accounting book value on the balance sheet. For service oriented groups like Jinhai Medical Technology, which often rely more on people, contracts and intangibles than heavy physical assets, P/B can sometimes look elevated. Even with that context, a 64x reading means the stock price is very high relative to its recorded equity base.
Set that beside the reference points in the data and the gap is clear. Management is running an unprofitable operation, with losses reported at HK$11.189m on revenue of HK$65.768m and a return on equity described as negative 18.35%. Losses have increased at about 61.3% per year over the past 5 years. Against that backdrop, the same checks flag the P/B as expensive versus both its direct peer group at 0.8x and the wider Asian Professional Services industry at 2x. That is a very steep premium to sectors where companies are profitable and carry far lower ratios.
On those metrics, the current preferred yardstick is sending a consistent message. The price to book figure of 64x is far above levels suggested by peer and industry comparisons, and the business is not profitable today based on the supplied data. Result: Price-to-book of 64x (OVERVALUED).
See what the numbers say about this price — find out in our valuation breakdown.
Still, the widening losses and heavily diversified operations outside core medical activities mean any earnings disappointment or sentiment shift could quickly pressure Jinhai Medical Technology’s rich multiple.
Find out about the key risks to this Jinhai Medical Technology narrative.
Next Steps
Concerned the tone here feels cautious rather than upbeat? Review the numbers on Jinhai Medical Technology yourself, consider acting promptly, and carefully evaluate the 2 important warning signs.
Looking for more ideas beyond Jinhai Medical Technology?
If Jinhai Medical Technology feels fully priced to you, broaden your watchlist now and give yourself more options before the next big move passes by.
- Target stability first by reviewing a list of solid balance sheet and fundamentals (203 results) that can help you focus on companies with stronger financial foundations.
- Hunt for potential mispricings through a 613 high quality undiscovered gems that highlights quality businesses the market may not be paying much attention to yet.
- Prioritise resilience by scanning a 231 resilient stocks with low risk scores so you can focus on businesses with fewer red flags and steadier profiles.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com